Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Morita, H; Kubo, Terufumi; Ruckert, B; Ravindran, Arun V; Soyka, M B; Rinaldi, A O; Sugita, Kazunari; Wawrzyniak, Marcin; Wawrzyniak, P; Motomura, Kenichiro; Tamari, M; Orimo, K; Okada, N; Arae, Ken; Saito, Kazuki; Altunbulakli, Can; Castro-Giner, Francesc; Tan, Ge; Neumann, A; Sudo, Katsuko; O'Mahony, L; Honda, K; Nakae, Susumu; Saito, H; Mjösberg, J; Nilsson, G E; Matsumoto, Kenji; Akdis, Mübeccel; Akdis, Cezmi A (2019). Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. Journal of Allergy and Clinical Immunology:Epub ahead of print.

Karbach, J; Neumann, A; Atmaca, A; Wahle, C; Brand, K; von Boehmer, L; Knuth, A; Bender, A; Ritter, G; Old, L J; Jäger, E (2011). Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clinical Cancer Research, 17(4):861-870.

Atmaca, A; Al-Batran, S E; Neumann, A; Kolassa, Y; Jäger, D; Knuth, A; Jäger, E (2009). Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study. Gynecologic oncology, 112(2):384-388.

Jäger, E; Gnjatic, S; Nagata, Y; Stockert, E; Jäger, D; Karbach, J; Neumann, A; Rieckenberg, J; Chen, Y T; Ritter, G; Hoffman, E; Arand, M; Old, L J; Knuth, A (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proceedings of the National Academy of Sciences of the United States of America, 97(22):12198-12203.

This list was generated on Thu May 23 21:17:55 2019 CEST.